Examkin

Question

Difficulty: HardPharmacologic Interventions

A 68-year-old man comes to the outpatient clinic for a follow-up examination regarding his heart failure. He was diagnosed with New York Heart Association (NYHA) class III heart failure with a reduced ejection fraction (HFrEF) six months ago. An echocardiogram at that time showed a left ventricular ejection fraction of 25%25\%. His past medical history is significant for hypertension, type 2 diabetes mellitus, and severe bilateral renal artery stenosis that was diagnosed via magnetic resonance angiography two years ago. His current medications include carvedilol, furosemide, and atorvastatin. The patient reports stable dyspnea on exertion but denies orthopnea, paroxysmal nocturnal dyspnea, or recent weight gain. Vital signs include a blood pressure of 142/86 mmHg142/86 \text{ mmHg} and a regular heart rate of 62 /min62 \text{ /min}. Physical examination reveals a jugular venous pressure of 6 cm H2O6 \text{ cm H}_2\text{O}. The lungs are clear to auscultation bilaterally, and there is no lower extremity edema. Laboratory studies show:

Serum sodium: 138 mEq/L138 \text{ mEq/L}
Serum potassium: 5.6 mEq/L5.6 \text{ mEq/L}
Blood urea nitrogen: 34 mg/dL34 \text{ mg/dL}
Serum creatinine: 2.2 mg/dL2.2 \text{ mg/dL}

Which of the following is the most appropriate next step in pharmacologic management to reduce this patient's long-term mortality?

  1. Initiate hydralazine and isosorbide dinitrateAnswer
  2. B
    Initiate ivabradine
  3. C
    Initiate lisinopril
  4. D
    Initiate spironolactone
  5. E
    Initiate verapamil

Answer

The most appropriate next step is to initiate hydralazine and isosorbide dinitrate.
The core goal in managing HFrEF is to optimize guideline-directed medical therapy to improve symptoms and reduce mortality. Standard mortality-reducing therapy includes a beta-blocker, a renin-angiotensin system inhibitor (ACE inhibitor, ARB, or ARNI), and a mineralocorticoid receptor antagonist (MRA). However, this patient has severe bilateral renal artery stenosis, which is an absolute contraindication to ACE inhibitors, ARBs, and ARNIs due to the risk of precipitating acute renal failure. Furthermore, his serum potassium is elevated (5.6 mEq/L5.6 \text{ mEq/L}) and he has significant chronic kidney disease, which contraindicates the use of an MRA like spironolactone. In patients with HFrEF who cannot tolerate standard renin-angiotensin-aldosterone system inhibition due to renal dysfunction, hyperkalemia, or bilateral renal artery stenosis, the combination of hydralazine and isosorbide dinitrate is indicated. This combination provides both arterial and venous vasodilation and has been shown to reduce mortality in this specific population.

Step-by-Step Solution

1
Identify the patient's primary condition and the clinical goal.
The patient has NYHA class III HFrEF (LVEF 25%25\%) and needs an additional medication to reduce long-term mortality.
Standard of care requires optimizing guideline-directed medical therapy to improve survival.
2
Evaluate standard first-line mortality-reducing options against the patient's comorbidities.
ACE inhibitors, ARBs, and ARNIs are contraindicated due to bilateral renal artery stenosis. MRAs (e.g., spironolactone) are contraindicated due to baseline hyperkalemia (5.6 mEq/L5.6 \text{ mEq/L}) and renal impairment.
Bilateral renal artery stenosis relies on angiotensin II for glomerular perfusion, and MRAs will exacerbate life-threatening hyperkalemia.
3
Determine the alternative pharmacologic intervention for mortality reduction in this specific clinical scenario.
The combination of hydralazine and isosorbide dinitrate is the correct choice.
This combination is proven to reduce mortality in HFrEF patients who cannot tolerate RAAS inhibition due to renal dysfunction or hyperkalemia.

Key Concept

In patients with heart failure with reduced ejection fraction (HFrEF) who cannot tolerate standard renin-angiotensin-aldosterone system (RAAS) inhibitors due to contraindications such as bilateral renal artery stenosis or severe hyperkalemia, the combination of hydralazine and isosorbide dinitrate is indicated to reduce mortality.
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic